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Tools for fully automated volumetric measurement 
of cerebral atrophy from MRI for routine 
clinical practice in diagnosing Alzheimer’s disease
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Abstract 
 Hippocampal atrophy is the best validated biomarker of Alzheimer’s disease (AD) and can be 
detected quantitatively by volumetric magnetic resonance imaging (vMRI). Fully automated vMRI software 
was developed to overcome many clinical translating hurdles of the manual and semi-automated methods. 
However,	there	are	no	data	of	sensitivity	and	specificity	of	vMRI	to	be	used	as	a	tool	to	diagnose	AD	in	
general clinical setting.  Moreover, the hippocampal atrophy can be found in various neurological conditions 
with memory impairments, not only the AD. This hippocampal atrophy results from vMRI should be 
accompanied by/with the clinical evaluation rather than be used alone.
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 Neurodegenerative disease such as 
Alzheimer’s disease (AD) is associated with a 
characteristic pattern of neuropathology spreading 
in the brain1. The progressive accumulations of 
abnormal proteins both amyloid-beta (Aβ) and 
hyperphosphorylated tau were found in the AD brain. 
This pathology occurs early in medial temporal lobe 
(entorhinal cortex and hippocampus) followed by 
progressive neocortical change2. These changes are 
accompanied with regional cerebral atrophy that can 
be detected noninvasively by volumetric magnetic 
resonance imaging (vMRI)3. Hippocampal atrophy 
is the best established and validated biomarker 
because it occurs in the early stage of disease and 
it is easy to identify and recognize the boundary 
on coronal MRI slices4.	 Methods	 of	 quantified	
hippocampal volume can be semi-quantitative 
visual rating scales or quantitative labor intensive 
manual tracing. Hippocampal volume is associated 
with the stages of AD and prodromal AD; otherwise 
known as mild cognitive impairment (MCI) and the 
conversion from MCI to AD5. Inclusion of biomarker 
e.g. hippocampal volume in the evaluation of the 
patient with memory complaint could improve the 
accuracy of early diagnosis of AD as in the proposed 
new criteria for early diagnosis of this disease6.
 Despite research supporting the value of 
vMRI in evaluating cognitive impairment, translation 
to clinical practice faces many hurdles7. There is no 
standard imaging protocol to select the appropriate 
clinical MRI parameters. The three-dimension output 
requires more scanning time and more data storage. 
vMRI procedures need high grey-white contrast 
that is not essential in general radiological practice. 
Spatial dimension varies across the scanners built 
by different manufacturers, versions, equipments 
and software8. The corrections of spatial distortion, 
motion or other artifacts are crucial in the volumetric 
procedures. Manual and semi-automated methods 
still require expert. Thus, inter- and intra-operator 
variability limits the generalizability. Application into 
clinical	workflow	which	is	related	to	images	format	
and output system is another important issue in 
routine clinical practice.          
 Many clinical translating hurdles have been 
overcome by using the large-scale, multicenter 
longitudinal neuroimaging biomarker study. 
One such example is the Alzheimer’s Disease 
Neuroimaging Initiative (ADNI) which had included 
800 elderly subjects comprising 200 elderly controls, 
400 amnestic mild cognitive impairment (aMCI) 
patients and 200 patients with early-onset AD9. This 
study has tried to develop the standardized and 
optimized imaging procedures aimed at bringing 
them to clinical practice. NeuroQuant (Cortechs, 
Inc., CA, USA), a US FDA-approved image analysis 
software provides fully automated volumetric 
measurements of several brain structures10. This 
fully automated vMRI software has provided 
standardization of image acquisition, correction of 
spatial distortions, improved data throughput, the 
possibility of generating normative database of brain 
structures volumes, reduced reliance on high-level 
expertise and decreased inter-operator variability. 
Moreover, these measures have been validated 
against the manual segmentation method11. 
 However, translation of such tools to routine 
clinical practice still faces some critical issues. The 
most important problem is that there are no data 
of	 sensitivity	and	 specificity	using	 these	 tools	 for	
diagnosing dementia such as AD in general clinical 
setting. Furthermore, the processes using these vMRI 
procedures still require qualitative visual review by 
an	expert	to	detect	significant	artifact	and	gross	brain	
abnormalities in segmentation errors12. Concerns 
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result has been correlated with the knowledge that 
the hippocampal atrophy can be found in various 
neurological conditions with memory problems. 
These include frontotemporal dementia (FTD)15, 
epilepsy16, schizophrenia17, traumatic brain injury18 
and depression19. This study has given the valuable 
information for consideration in routine clinical 
use because the research was conducted in real 
clinical setting. The diversity of patients are seen 
and the pretest probability of clinical criteria is low 
as compared with the laboratory-based research7.
 Even though the fully automated vMRI tools 
have been still facing some problems in translation 
to routine clinical practice, there has been a guidance 
for using these tools supporting the clinical diagnosis 
of patients with memory problems7. Firstly, if the 
clinical impression is neurodegenerative disease, 
volumetric data should be used as supportive 
evidence. Secondly, if the clinical impression is 
the absence of neurodegenerative disease, normal 
values from vMRI should be used to reassure the 
patients who worry about their health. Finally, if the 
clinical impression is early-onset AD but the vMRI 
values show normal or minimal neurodegeneration 
of memory structures, the less common or 
reversible causes of memory impairment should be 
investigated thoroughly e.g. medication side effects 
and depressive pseudodementia.
 Conclusion
 It would seem that the tools for fully auto-
mated vMRI are still not ready for routine clinical 
use in diagnosing the Alzheimer’s disease. However, 
these tools could be used as supporting information 
for clinical diagnosis. More researches with these 
measures in relatively unselected patients seen 
in clinical practice are needed to translate such 
scientific	knowledge	 into	routine	clinical	practice. 
about extra expense and time consumption for 
additional processes of the software are the other 
issues to be considered as well13.
 Recently, there was a clinical practice-based 
study using fully automated vMRI for diagnosing 
dementia of Alzheimer’s type14. One hundred and 
twenty-two elderly patients referred to the memory 
clinic at Oslo University Hospital were analyzed 
using NeuroQuant to quantify the volumes of 
various brain structures. Two doctors separately 
made clinical diagnosis of dementia types using 
ICD-10 criterion with blindness of the MRI results. 
The receiver operating characteristic (ROC) analysis 
and area under the curve (AUC) calculation were 
performed. The results showed that the mean age 
was 67.2 years, and 60 percent were men.   
 Sixty-three patients were diagnosed with 
dementia of Alzheimer’s type, 24 patients were 
dementia with other types, 25 patients had MCI 
and 10 patients had subjective cognitive impairment 
(SCI). This volumetric MRI method could distinguish 
patients with Alzheimer’s dementia from those 
without dementia, but could not distinguish from 
those with other types of dementia. Brain structures 
in	 which	 volumes	 were	 significantly	 different	
between patients with Alzheimer’s dementia and 
those without dementia included the hippocampus, 
amygdala, putamen, anterior cortex, cortical 
gray matter, lateral ventricles and inferior lateral 
ventricles. The best threshold proportional volume 
of the hippocampus per intracranial cavity which 
could be used to distinguish patients with AD from 
those without dementia was 0.48 percent with 
74	 percent	 sensitivity	 and	 71	 percent	 specificity.	
Because the vMRI procedure cannot distinguish 
the AD patients from those with other types of 
dementia, it should support the result of clinical 




1. Braak H, Braak E. Evolution of the neuropathology of Alzheimer’s disease. Acta Neurol Scand Suppl 
1996;165:3-12.
2. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 
1991;82(4):239-59.
3.	 Delaère	P,	Duyckaerts	C,	Brion	JP,	et	al.	Tau,	paired	helical	filaments	and	amyloid	in	the	neocortex:	
a morphometric study of 15 cases with graded intellectual status in aging and senile dementia of 
Alzheimer type. Acta Neuropathol 1989;77(6):645-53.
4. Atiya M, Hyman BT, Albert MS, et al. Structural magnetic resonance imaging in established and 
prodromal Alzheimer disease: a review. Alzheimer Dis Assoc Disord 2003 Jul-Sep;17(3):177-95.
5. Frisoni GB, Fox NC, Jack CR, et al. The clinical use of structural MRI in Alzheimer disease. Nat Rev 
Neurol 2010 Feb;6(2):67-77.
6. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer’s disease: 
revising the NINCDS-ADRDA criteria. Lancet Neurol 2007 Aug;6(8):734-46.
7. Brewer JB. Fully-automated volumetric MRI with normative ranges: translation to clinical practice. 
Behav Neurol 2009;21(1):21-8.
8. Jack CR, Bernstein MA, Fox NC, et al. The Alzheimer’s Disease Neuroimaging Initiative (ADNI): MRI 
methods. J Magn Reson Imaging 2008 Apr;27(4):685-91.
9. Mueller SG, Weiner MW, Thal LJ, et al. Ways toward an early diagnosis in Alzheimer’s disease: the 
Alzheimer’s Disease Neuroimaging Initiative (ADNI). Alzheimers Dement 2005 Jul;1(1):55-66.
10.	 Brewer	 JB,	Magda	 S,	 Airriess	 C,	 et	 al.	 Fully-automated	quantification	 of	 regional	 brain	 volumes	 
for improved detection of focal atrophy in Alzheimer disease. AJNR Am J Neuroradiol 2009 
Mar;30(3):578-80.
11.	 Kovacevic	S,	Rafii	MS,	Brewer	JB,	Initiative	AsDN.	High-throughput,	fully	automated	volumetry	for	
prediction of MMSE and CDR decline in mild cognitive impairment. Alzheimer Dis Assoc Disord 2009 
Apr-Jun;23(2):139-45.
12. McEvoy LK, Brewer JB. Quantitative structural MRI for early detection of Alzheimer’s disease. Expert 
Rev Neurother 2010 Nov;10(11):1675-88.
13.	 Desikan	RS,	Rafii	MS,	Brewer	JB,	et	al.	An	expanded	role	for	neuroimaging	in	the	evaluation	of	memory	
impairment. AJNR Am J Neuroradiol 2013 Nov;34(11):2075-82.
14.	 Engedal	K,	Brækhus	A,	Andreassen	OA,	et	al.	Diagnosis	of	dementia--automatic	quantification	of	
brain structures. Tidsskr Nor Laegeforen 2012 Aug;132(15):1747-51.
15. Frisoni GB, Laakso MP, Beltramello A, et al. Hippocampal and entorhinal cortex atrophy in 
frontotemporal dementia and Alzheimer’s disease. Neurology 1999 Jan;52(1):91-100.
16. Cendes F. Progressive hippocampal and extrahippocampal atrophy in drug resistant epilepsy. Curr 
Opin Neurol 2005 Apr;18(2):173-7.
Journal of Medicine and Health Sciences
(Vol.22 No.1 April 2015)98
17.	 Honea	 R,	 Crow	 TJ,	 Passingham	 D,	 et	 al.	 Regional	 deficits	 in	 brain	 volume	 in	 schizophrenia:	 
a meta-analysis of voxel-based morphometry studies. Am J Psychiatry 2005 Dec;162(12):2233-45.
18. Immonen RJ, Kharatishvili I, Gröhn H, et al. Quantitative MRI predicts long-term structural and 
functional outcome after experimental traumatic brain injury. Neuroimage 2009 Mar;45(1):1-9.
19. Kanner AM. Structural MRI changes of the brain in depression. Clin EEG Neurosci 2004 Jan;35(1): 
46-52.
